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Drug toxicity predictionAnticancer drug-associated side effect knowledge often exists in multiple heterogeneous and comple-
mentary data sources. A comprehensive anticancer drug–side effect (drug–SE) relationship knowledge
base is important for computation-based drug target discovery, drug toxicity predication and drug repo-
sitioning. In this study, we present a two-step approach by combining table classiﬁcation and relation-
ship extraction to extract drug–SE pairs from a large number of high-proﬁle oncological full-text
articles. The data consists of 31,255 tables downloaded from the Journal of Oncology (JCO). We ﬁrst
trained a statistical classiﬁer to classify tables into SE-related and -unrelated categories. We then
extracted drug–SE pairs from SE-related tables. We compared drug side effect knowledge extracted from
JCO tables to that derived from FDA drug labels. Finally, we systematically analyzed relationships
between anti-cancer drug-associated side effects and drug-associated gene targets, metabolism genes,
and disease indications. The statistical table classiﬁer is effective in classifying tables into SE-related
and -unrelated (precision: 0.711; recall: 0.941; F1: 0.810). We extracted a total of 26,918 drug–SE pairs
from SE-related tables with a precision of 0.605, a recall of 0.460, and a F1 of 0.520. Drug–SE pairs
extracted from JCO tables is largely complementary to those derived from FDA drug labels; as many as
84.7% of the pairs extracted from JCO tables have not been included a side effect database constructed
from FDA drug labels. Side effects associated with anticancer drugs positively correlate with drug target
genes, drug metabolism genes, and disease indications.
 2014 Elsevier Inc. All rights reserved.1. Introduction eﬁt from the vast amount of higher-level clinical phenotype dataDrug-induced side effects are observable phenotypes of drugs
manifested at the level of the whole body system and are mediated
by a drug interacting with its on- or off-targets through a cascade
of downstream pathway perturbations. Systematic and integrated
approaches to studying drug-associated side effects have the
potential to illuminate the complex pathways of drug-induced tox-
icities, allowing for the identiﬁcation of novel drug targets, predic-
tion of unknown drug toxicities, and repositioning of existing
drugs for new disease indications.
Computational approaches to drug target discovery,
unknown drug toxicities prediction, and drug repositioning have
primarily relied on drug molecular structures or functions such
as chemical structure, molecular activity, and molecular docking
[2,7,11,14,17,18,20,26,34,35]. These computational approaches
largely depend on the availability of drug molecular structure or
function knowledge bases. Systems approaches would greatly ben-such as observed drug-related side effects [3,5,6,13]. It has been
increasingly recognized that similar side effects of seemingly unre-
lated drugs can be caused by their common off-targets and that
drugs with similar side effects are likely to share molecular targets
[5]. Therefore, systems approaches to studying the phenotypic
relationships among drugs and integrating the high-level drug
phenotypic data with lower-level genetic and chemical data will
allow for a better understanding of drug toxicities. Current systems
approaches to studying phenotypic relationships among drugs rely
exclusively on information extracted from FDA drug labels [3,5,17].
It was recently demonstrated that 39% of serious events associated
with targeted anticancer drugs are not reported in clinical trials
and 49% are not described in initial FDA drug labeling [21]. For
the successful development of phenotype-driven systems
approaches to understanding drug-associated side effects, the
availability of a comprehensive and machine-understandable
drug–side effect (SE) relationship knowledge base is critical.
Drug–SE relationship extraction and mining from multiple het-
erogeneous and complementary data sources is an active research
area. Kuhn et al. developed text mining approaches in constructing
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SIDER represents the best source of computable drug side effect
association knowledge. Systems approaches to studying this infor-
mation have led to the prediction of several new drug targets
[5,17]. The FDA Adverse Event Reporting System (FAERS) is the
spontaneous reporting system overseen by the U.S. FDA and the
main resources for post-marketing drug safety surveillance. Min-
ing drug–side effect (drug–SE) relationships from FAERS is a highly
active research area. Data mining algorithms such as dispropor-
tionality analysis, correlation analysis, multivariate regression,
and signal ranking and ﬁltering leveraging external knowledge
have been developed to detect adverse drug signals from FAERS
[1,12,23,28,29]. Another important information source of drug–SE
associations is the vast amount of published biomedical literature.
Currently, more than 22 million biomedical abstracts are publicly
available on MEDLINE, making it a rich source of side effect infor-
mation for drugs at all clinical stages, including drugs in pre-mar-
keting clinical trials, post-marketing clinical case reports and
clinical trials. Statistical, machine learning and signal ranking
approaches have been developed in extracting drug–SE pairs from
free-text MEDLINE abstracts [9,22,27,30,31]. Recently, researchers
began to explore other data sources for mining drug–SE associa-
tions. For example, patient EHRs have emerged as a promising
resource for post-marketing drug adverse event discovery
[8,19,32]. Health information available on the web and web search
log data can also provide valuable information on drug side effects
[16,33]. In summary, drug side effect association knowledge exists
in multiple heterogeneous and complementary data sources with
different formats. The effectiveness of automatic approaches in
extracting drug side effect knowledge depends on both data
sources and the targeted drugs or SEs. Currently, there exist no uni-
versally effective approaches to extract this knowledge from differ-
ent data sources.
While the main data sources used in previous studies for drug–
SE relationship extraction include FDA drug labels, abstracts of
published biomedical literature and post-marketing drug safety
surveillance systems, there exists a large body of untapped drug
side effect knowledge that remains buried in full-text articles. In
this study, we developed automatic approaches to extract antican-
cer drug–SE pairs from the Journal of Clinical Oncology (JCO), spe-
ciﬁcally the tables imbedded in the full text articles. JCO was
established in 1983 and is the ofﬁcial journal of the American Soci-
ety of Clinical Oncology and the leading journal in oncology. JCO
articles include a variety of cancer-related research articles, includ-
ing clinical trials reporting drug efﬁcacy and toxicity in cancer
patients, trial reports evaluating the effectiveness of biomarkers,
clinical case reports, and meta-analysis studies, among other arti-
cle types. JCO articles not only include pivotal clinical trials that
have led to drug approval, but also trials that are still in investiga-
tional stages, and even failed trials. Side effect knowledge of drugs
at different clinical stages is crucial to our understanding of the
molecular mechanisms underlying the observed toxicities.2. Approach
In this pilot study, we focused on extracting drug–SE pairs from
tables contained in full-text JCO articles. Unlike the full-text por-
tions of JCO articles, the tables often summarize important infor-
mation such as patient characteristics, treatment outcomes, and
toxicities, with each table often containing only one type of infor-
mation. We downloaded a total of 13,855 full text articles from JCO
and extracted 31,255 tables from the downloaded articles. Since
not all tables are related to drug side effects, we ﬁrst developed a
support vector machine classiﬁer to classify tables into SE-related
or -unrelated categories. We then extracted drug–SE pairs fromthe SE-related tables. The precisions of the input lexicons (both
drug lexicon and SE lexicon) are critically important for subsequent
relationship extraction. We created a clean drug lexicon and a
clean SE lexicon through intense manual curation efforts. Using
the clean lexicons, we extracted drug–SE pairs from classiﬁed
tables using dictionary-based approaches. In order to compare
our study to existing research efforts in building drug–SE relation-
ship knowledge base, we compared drug–SE pairs that we
extracted from JCO tables to those from SIDER, currently the best
drug side effect association database constructed from FDA pack-
age inserts [15]. To show the potential of extracted drug–SE pairs
in developing systems approaches to understand the molecular
mechanisms underlying the observed drug phenotypes (toxicities),
we linked drugs to their corresponding gene targets, metabolism
genes, and disease indications and systematically studied the cor-
relations between drug phenotypes and their known targets,
metabolism genes, and disease indications. To the best of our
knowledge, this is the ﬁrst study in combining table classiﬁcation
and relationship extraction in order to extract drug–SE pairs from
full-text articles.3. Data and methods
The system consists of the following steps: (1) we downloaded
JCO articles and extracted tables from downloaded articles; (2) we
created clean drug and SE lexicons; (3) we classiﬁes tables into
drug toxicity-related and non-related categories; (4) we extracted
drug–SE pairs from classiﬁed tables using manually curated, clean
drug and SE lexicons; (5) we compared drug–SE pairs extracted
from JCO tables to those derived from FDA drug labels; and (6)
we systematically analyzed the relationships between cancer
drug-associated side effects with drug gene targets, drug metabo-
lism, and disease indications (Fig. 1).
3.1. Download JCO articles and extract tables
We downloaded a total of 13,855 JCO full text articles (1.5 GB)
published between 1983 and 2013 from the Case Western Reserve
University Intranet. We then extracted a total of 31,255 tables from
these downloaded JCO articles. A typical JCO clinical trial paper
often contains multiple tables describing trial participants, treat-
ment response, survival, prognostic factors, treatment costs, or
treatment-related adverse events. While some articles contain no
tables, others include many tables. For example, the article entitled
‘‘Procarbazine, Lomustine, and Vincristine (PCV) Chemotherapy for
Anaplastic Astrocytoma: A Retrospective Review of Radiation Ther-
apy Oncology Group Protocols Comparing Survival With Carmus-
tine or PCV Adjuvant Chemotherapy’’ (PMID 10550132) contains
as many as 14 tables.
The content associated with each extracted table includes the
article title, table content, and table legend. While the side effect
information is included in the table content and table legends,
the drug information is often included in the article titles. A typical
example of a SE-related table is shown in Fig. 2. We used the pub-
licly available information retrieval library Lucene (http://lucene.a-
pache.org) to create a search engine with indices created on article
titles, table contents, and table legends. Each table was assigned a
unique identiﬁcation number.
3.2. Create clean drug and SE lexicons
3.2.1. Create clean anticancer drug lexicon
We ﬁrst compiled a comprehensive drug lexicon from the
Uniﬁed Medical Language System (UMLS) (2011AB version) [4]
using terms with the following semantic types: ‘‘Pharmacologic
Fig. 1. Experiment ﬂowchart.
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‘‘Antibiotic’’ (10,423 terms), ‘‘Steroid’’ (21,193 terms), and ‘‘Vita-
min’’ (3630 terms). Note that many terms from the last three cat-
egories were not included in the category ‘‘Pharmacologic
Substance.’’ This drug lexicon consists of 791,848 terms, which
includes not only FDA-approved but also investigational drugs, as
well as failed drugs. Inclusion of both investigational and failed
drugs in the drug lexicon is important in extracting drug–SE pairs
from JCO articles.
The initial drug lexicon contains both cancer drugs and non-
cancer drugs. To facilitate our task of building a cancer-speciﬁcFig. 2. A typical example table that contains drug-associated adverse evdrug–SE knowledge base from JCO articles, we created a cancer-
speciﬁc drug lexicon from the initial drug lexicon through a com-
bination of automatic ﬁltering and manual curation. First, we ﬁl-
tered the initial drug lexicon with JCO tables, including both
table titles and legends. We used each drug term as a search query
to the local search engine. Terms that did not appear in any tables
were removed. This ﬁltering step removed many terms such as
‘‘zinc cl/b-caine/cetylpyrd cl unidentiﬁed’’ and ‘‘zinc ﬁnger and
btb domain containing 7c protein, human.’’ The ﬁltering signiﬁ-
cantly decreased the size of the drug lexicon, which was important
for our subsequent manual curation effort. In addition, this ﬁlteredent information. Drug information was contained in the article title.
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drugs that appeared in JCO articles were included. The ﬁltered lex-
icon consisted of 4988 drugs. We then manually curated the ﬁl-
tered lexicon by removing terms that are too general, ambiguous,
or mis-classiﬁed such as ‘‘drug’’, ‘‘medicine’’, ‘‘link,’’ ‘‘alerts,’’
‘‘align,’’ and ‘‘unknown.’’ The ﬁnal clean and cancer-speciﬁc drug
lexicon consists of 4256 terms.
3.2.2. Clean SE lexicon
An accurate and comprehensive SE lexicon is critical for drug–
SE relationship extraction. In our previous studies, we have manu-
ally curated a clean SE lexicon [28–31]. The clean SE lexicon con-
sists of 49,625 terms.
3.3. Classify tables into drug SE-related and -unrelated
3.3.1. Table classiﬁer training
From the downloaded tables, we removed tables containing no
drug or SE terms since no drug–SE pairs would be extracted from
these tables. We randomly selected 700 tables from remanning
tables and manually classiﬁed these tables into positives or
drug–SE-related (380 tables) and negatives (320 tables). We then
trained an SVM classiﬁers with Weka [10] using these manually
classiﬁed tables as training data. The SVM-based table classiﬁer
used polynomial kernel, bag-of-words feature, TF-IDF weighting,
stemming and stopwords-removal. The bag-of-words feature was
used since it is often the case that the appearance of one speciﬁc
word such as toxicity or adverse can determine whether or not a
sentence is drug–SE-related. The 10-fold cross validation was used
in training the table classiﬁer. During the training and testing of
the SVM classiﬁer, we experimented with different ways to process
the tables: (1) tables with html tags; (2) tables without html tags;
and (3) tables with html tags and removed table titles.
3.3.2. Evaluation
To test the performance of table classiﬁcation, we randomly
selected 100 JCO full-text articles and extracted a total of 375
tables from these articles, an average of 3.75 tables per article.
We ﬁrst manually classiﬁed these tables into SE-related and non-
related. Among the 375 tables, 34 were positives, which was less
than one per article. This indicates that most JCO tables are not
SE-related; therefore, ﬁnding SE-related tables before drug–SE
relationship extraction is critical. We used the manually classiﬁed
375 tables as our gold standard to evaluate the performance of the
SVM table classiﬁer.
3.4. Extract drug–SE pair from classiﬁed tables
3.4.1. Drug–SE pair extraction
We ﬁrst classiﬁed all JCO tables using the trained table classiﬁer
and recorded the article IDs for positively classiﬁed tables. We used
each drug from the drug lexicon as search query to the local JCO
table search engine. If a drug appeared in a table title, table con-
tent, or a table legend, the drug and the article ID were recorded.
Then we used each term from the SE lexicons as a search query
to the local JCO table search engine. Unlike our search for drug
terms, we only searched the table contents for SE terms.
Table titles and legends were not used since they often contain
drug–disease treatment relationships (as shown in Fig. 2). SE terms
along with the IDs of the tables in which they appeared were
recorded. Drug–SE pairs (along with article IDs) were extracted
by joining the article IDs.
3.4.2. Evaluation
Among the 375 tables extracted from the 100 randomly
selected JCO articles, 34 were SE-related as determined by manualcuration. From these SE-related tables, we extracted a total of 588
distinct drug–SE pairs, representing 32 drugs and 205 SEs. We
evaluated our algorithm in three different ways to investigate
how table classiﬁcation contributes to the subsequent relationship
extraction: (1) apply relationship extraction algorithm to all 375
unclassiﬁed tables; (2) use the SVM classiﬁer to classify these
tables ﬁrst, and then apply the algorithm to those positively classi-
ﬁed tables; and (3) apply the algorithm to the 34 tables that were
manually classiﬁed as positives. Standard precision, recall, F1, FPR
(false positive rate) and FNF (false negative rate) were calculated.
3.5. Compare drug–SE pairs extracted from JCO tables to ones derived
from FDA drug labels
In order to compare our study with existing research efforts in
building drug–SE relationship databases, we compared drug–SE
pairs that we extracted from JCO tables to those from SIDER, which
represents the best drug side effect association database con-
structed from FDA drug labeling so far. We downloaded a total of
100,049 known drug–SE pairs from SIDER and ﬁltered out drug–
SE pairs if the drugs did not appear in the cancer-speciﬁc drug lex-
icon we constructed above. After the ﬁltering, the SIDER dataset
consisted of 51,341 pairs. We evaluated coverages of targeted anti-
cancer drug-associated side effects in these two databases. Specif-
ically, we investigated whether JCO tables contained additional
side effect information for these innovative cancer drugs, which
have not been captured in FDA drug labeling. Targeted cancer
drugs control cancer cell growth by interfering with speciﬁc molec-
ular targets involved in tumor growth and progression. While tar-
geted anticancer drugs dramatically improve cancer treatment
outcomes, they are often associated with unexpectedly high toxic-
ities. We obtained a list of 45 targeted cancer drugs from the
National Cancer Institute (NCI) (http://www.cancer.gov/cancertop-
ics/factsheet/Therapy/targeted). We ﬁltered drug–SE pairs
extracted from JCO tables and from SIDER with the targeted cancer
drug list and compared the overlap of this knowledge between
these two data sources.
3.6. Analyze the correlation between drug side effects and drug targets,
metabolism and indications
We investigated the potential value of anticancer drug–SE pairs
that were extracted from JCO tables to our understanding of the
underlying drug molecular targets, drug toxicity prediction, and
drug repurposing. Speciﬁcally, we investigated whether drug–drug
pairs that share side effects also tend to share target genes, drug
metabolism genes, or disease indications.
3.6.1. Correlation with drug targets
We extracted a total of 10,478 drug–gene pairs from DrugBank
[25], representing 3454 drugs and 1816 genes. For drug–drug pairs
that share SEs at different cutoffs, we calculated the average num-
ber of shared gene targets.
3.6.2. Correlation with drug metabolizing genes
Similar to the correlation analysis above, we analyzed the corre-
lation between shared metabolism genes and overlapping SEs
between drugs. We obtained from PharmGKB [24] a total of 4399
drug–gene pairs with subtypes of pharmacokinetics (PK) or phar-
macodynamics (PD), representing 637 drugs and 859 genes. For
drug–drug pairs that share SEs at different cutoffs, we calculated
the average number of shared metabolism genes.
3.6.3. Correlation with drug indications
We extracted a total of 52,066 drug–disease pairs from Clinical-
Trials.gov (http://www.clinicaltrials.gov/), a registry of federally
Table 2
Precisions, recalls, and F1s of drug–SE extraction from three types of tables: positive
tables as determined by SVM classiﬁer, positive tables as determined manually, and
all 375 tables. Highlighted are best performances achieved for each type of tables.
Table classiﬁcation Drug Source Precision Recall F1
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States and around the world (www.clinicaltrials.gov). The drug–
disease pairs contain 2035 drugs and 9591 diseases. For drug–drug
pairs that share SEs at different cutoffs, we calculated the average
number of shared disease indications.SVM classiﬁed tables Title 0.605 0.469 0.529
All 0.490 0.476 0.483
Manually classiﬁed tables Title 0.684 0.471 0.558
All 0.554 0.478 0.513
All (unclassiﬁed) Title 0.491 0.471 0.481
All 0.288 0.478 0.3594. Results
4.1. The SVM-based table classiﬁer is effective in categorizing tables
into SE-related and -unrelated
We trained the SVM table classiﬁer on 700 manually classiﬁed
tables and tested it on a separate set of 375 tables extracted from
100 randomly selected JCO articles. We trained and evaluated the
classiﬁcation performance on tables processed in three different
ways: tables with HTML tags, tables without HTML tags, and tables
with neither HTML tags nor titles. Table 1 listed the precisions,
recalls, F1 measures, false positive rates (FPRs), and false negative
rates (FNRs) of the table classiﬁcation task. As shown in the table,
the classiﬁer achieved a precision of 0.711, recall of 0.941, and an
F1 value of 0.810 when it was trained and evaluated using tables
with HTML tags removed. Both the false positive and false negative
rates were low.Table 3
Drug–SE pairs extracted from JCO tables vs. pairs extracted from FDA drug labels.
Drug type Source Drugs (n) SEs (n) Pairs (n)
All cancer drugs JCO tables 520 1198 14,516
FDA drug labels 470 3431 58,454
Targeted cancer drugs JCO tables 31 584 1,984
FDA drug labels 15 837 2,419
Table 4
Overlap of drug–SE pairs between JCO tables and FDA drug labels: percent of drug–SE4.2. Drug–SE relationship extraction from classiﬁed tables
We manually extracted 588 drug–SE pairs from 34 positive
tables from a total of 375 tables extracted from the randomly
selected 100 JCO articles. Using these pairs as gold standard, we
compared the performance of pair extraction from SVM-classiﬁed
tables to those from manually classiﬁed tables and from unclassi-
ﬁed tables. As shown in Table 2, compared to relationship extrac-
tion from unclassiﬁed tables (all 375 tables), drug–SE
relationship extraction from SVM-classiﬁed tables had signiﬁcantly
better precision (0.605 vs. 0.491), while recalls were similar (0.469
vs. 0.471). Compared to relationship extraction from manually
classiﬁed tables, extraction from SVM-classiﬁed tables had compa-
rable precisions (0.605 vs. 0.684) and recalls (0.469 vs. 0.471). In
summary, drug–SE relationship extraction from automatically
classiﬁed tables had achieved comparable performance to that
from manually classiﬁed tables and signiﬁcantly improved perfor-
mance compared to that from unclassiﬁed tables. These results
demonstrated that table classiﬁcation before drug–SE relationship
extraction was necessary and our table classiﬁer was effective in
ﬁnding SE-related tables from all downloaded tables.
However, both precisions and recalls are still modest for both
SVM- and manually-classiﬁed tables. Based on our observations,
many SE-related tables contain drug–disease pairs that are not
related to drug side effects. For instance, many SE-related tables
contain disease terms that are used to describe patient disease
characteristics, co-morbidities, or exclusion criteria. Currently, we
are developing approaches to further improve the precision by
automatically ﬁltering out drug–disease treatment pairs, co-mor-
bidities and other noises. The modest recall achieved in our study
(0.469) indicates that the coverage of the underlying drug or SE
lexicon is not perfect. For instance, many SE terms appeared inTable 1
Table classiﬁcation performance. The best performance was achieved when HTML
tags were removed (highlighted).
Table preprocessing Precision Recall F1 FPR FNR
With HTML tags 0.322 0.853 0.467 0.178 0.147
Without HTML tags 0.711 0.941 0.810 0.038 0.058
Without HTML tags + no title 0.704 0.911 0.794 0.038 0.088the tables but were not included in the SE lexicon that we built
based on MedDRA. Currently, we are developing approaches to
build a more comprehensive SE lexicon.4.3. Compare drug–SE pairs extracted from JCO tables to ones derived
from FDA drug labels
From all tables classiﬁed as positives, we extracted a total of
26,918 drug–SE pairs, representing 520 anticancer drugs and
1198 SE terms. From SIDER, we obtained a total of 58,454 antican-
cer drug–SE pairs using the same drug lexicon that we created, rep-
resenting 470 drugs and 3431 SE terms (Table 3). Drug–SE pairs
extracted from JCO tables included more drugs than those from
FDA drug labels, which was expected since JCO articles included
not only FDA-approved drugs but also experimental and failed
drugs while FDA drug labels contain exclusively approved drugs.
Since targeted anticancer drugs were relatively new than other
anticancer drugs, we compared the coverages of drug–SE pairs
for these innovative drugs between the two data resources.
Drug–SE pairs extracted from JCO tables contained 31 of the 45 tar-
geted cancer drugs that we downloaded from NCI. These 31 tar-
geted cancer drugs were associated with 1,984 drug–SE pairs in
JCO tables. The SIDER database contains 15 of the 45 targeted can-
cer drugs and 14 of these 15 drugs also appeared in JCO tables.
We then calculated the overlap between drug–SE pairs
extracted from JCO tables and those from SIDER. As shown in
Table 4, 15.3% of drug–SE pairs extracted from JCO tables appeared
on FDA drug labels and 3.8% of pairs derived from FDA drug labels
also appeared in JCO tables. We observed similar trends for tar-
geted cancer drugs. These results indicate that drug toxicity knowl-pairs from source 1 (column) that also appeared in source 2 (row).
Drug type JCO tables
(%)
FDA drug labels
(%)
All JCO tables 100 3.8
FDA drug
labels
15.3 100
Targeted cancer
drugs
JCO tables 100 22.9
FDA drug
labels
27.9 100
R. Xu, Q. Wang / Journal of Biomedical Informatics 53 (2015) 128–135 133edge in these two data sources is largely complementary. While
FDA drug labels contained known side effect information for com-
mercial drugs from many data resources including published clin-
ical trials and post-market drug safety surveillance systems, JCO
tables contained side effect information for many cancer drugs that
are still in experimental stages. Therefore, in order to build a com-
prehensive drug–SE relationship knowledge base, drug–SE pairs
from multiple complementary data sources such as JCO articles,
FDA drug labels, biomedical literature, and post-market drug safety
surveillance systems are needed.4.4. Anticancer drug-associated side effects positively correlate with
drug-associated targeted genes, metabolizing genes, and disease
indications
Our ultimate goal in building a cancer-speciﬁc drug–SE rela-
tionship knowledge base is to develop computational approaches
to discover novel cancer drug targets, predict unknown drug side
effects in cancer patients, and ﬁnd new indications for existing
drugs. To demonstrate the potential of drug–SE pairs extracted
from JCO tables in these applications, we investigated whether
drug pairs that shared side effects (SEs) also tended to share gene
targets, metabolism genes, and disease indications. We investi-
gated whether any differences existed between targeted anticancer
drug–SE pairs and all anticancer drug–SE pairs. Different from tra-
ditional cytotoxic chemotherapy drugs that kill both tumor and
healthy cells, targeted cancer drugs control cancer cell growth by
interfering with speciﬁc molecular targets that are predominantly
expression on tumor cells. Therefore, side effects for targeted can-
cer drugs are presumably mostly mechanism-based and should
correlate more strongly with their gene targets.
We showed that cancer drug-associated side effects positively
correlated with drug targets (Fig. 3). For all drug–drug combina-
tion, the average number of shared gene targets was 0.608, and
the number signiﬁcantly increased to 0.817 for drug–drug pairs
that shared at least 30 SEs and to 1.028 for drug–drug pairs that
shared at least 50 SEs. The positive correlation was stronger for tar-
geted cancer drugs. For targeted cancer drugs, the average number
of shared gene targets signiﬁcantly increased from 1.649 for all
drug–drug combinations to 2.741 for pairs that shared at least 50
SEs. The stronger correlation between side effects and gene targets
for targeted cancer drugs may be due to the fact that many side
effects for targeted cancer drugs are caused by the on-target effects
(by the drug binding to ‘on-target’ in normal cells). On the other
hand, side effects for non-speciﬁc cytotoxic chemotherapy drugs
are similar even though the drugs can have different targets. For
example, irinotecan is a cytotoxic DNA topoisomerase I inhibitor
primarily used in the treatment of colorectal cancer. Cisplatin isFig. 3. Correlation between shared SEs and shared target genes.a platinum-compound chemotherapy drug that acts as an alkylat-
ing agent. Even though these two drugs have different targets, they
share many systemic side effects such as alopecia and neutropenia.
Therefore, it is less likely to predict drug targets based on shared
side effects for chemotherapy drugs.
Both drug targets and metabolism genes are involved in drug-
induced side effects. We showed that cancer drug-associated side
effects strongly correlated with drug metabolism genes (Fig. 4).
Unlike the correlation with gene targets, the correlation with drug
metabolism genes was weaker for targeted agents than for all can-
cer drugs. For all cancer drugs, the average number of shared
metabolism genes increased from 0.977 for all drug–drug combi-
nations to 4.33 for drug–drug pairs that shared at least 50 SEs.
For targeted cancer drugs, the average number of shared metabo-
lism genes increased from 0.438 for all drug–drug combinations
to 1.069 for drug–drug pairs that shared at least 50 SEs. The
observed positive correlation between side effects and drug metab-
olism genes indicates that computational models for predicting
drug toxicities in cancer patients needs to incorporate not only
known drug on-target genes, but also drug metabolism genes.
The observed phenotypic drug side effects strongly correlated
with drug indications (Fig. 5). For all cancer drugs, the average
number of shared disease indications was 6.859 for all drug–drug
combinations; the number signiﬁcantly increased to 24.33 for
drug–drug pairs that shared at least 20 SEs, and to 46.15 for pairs
that shared at least 50 SEs. The correlation with disease indications
was weaker for targeted cancer drugs. For targeted cancer drugs,
the average number of shared disease indications was 17.88 for
all drug combinations and the number increased to 25.68 for drug
pairs that shared at least 30 SEs and to 37.42 for drug pairs that
shared at least 50 SEs. The positive correlation between cancer
drug-associated side effects and their disease indications indicates
that we may repurpose existing drugs for new cancer treatments
or cancer drugs for non-cancer treatments based on the clinically
observed drug-associated side effects.5. Discussion
We presented a system that combined both table classiﬁcation
and relationship extraction to effectively extract a large number of
drug–SE pairs from high proﬁle oncological articles. Nonetheless,
further improvements to our study can be made in the future. First,
while tables in JCO articles summarize important side effects for
speciﬁc studies, it remains unknown whether they captured allFig. 4. Correlation between shared SEs and shared metabolism genes.
Fig. 5. Correlation between shared SEs and shared disease indications.
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may be discussed in articles, but not summarized in tables. Cur-
rently, we are developing approaches to extract drug–SE pairs from
the text parts of JCO articles. Second, even with manually curated
drug lexicons and SE lexicons, the precision and recall of drug–SE
pair extraction from SVM-classiﬁed and even manually-classiﬁed
tables are still modest (precision: 0.605; recall: 0.469). The modest
precisions indicate that SE-related tables still contain many non-
drug–SE pairs. The modest recalls indicate that the coverages of
the drug lexicon and especially the SE lexicon need to be improved.
Third, the extracted drug–SE pairs are only for individual drugs. In
reality, cancer drugs are often used with other drugs in speciﬁc
combinations. Certain side effects may occur only when speciﬁc
drug–drug combinations are used. Extracting side effects associ-
ated with drug combinations is a challenging task and related work
is scant. Fourth, many drug toxicity-speciﬁc tables included fre-
quency or prevalence information for reported side effects. For tai-
loring treatments to speciﬁc cancer patients, both the presence and
the prevalence of drug-associated side effects are important. Cur-
rently, we are exploring the structures of the tables to automati-
cally extract this information. Fifth, even though JCO is the
leading journal in oncology, many other high proﬁle medical jour-
nals such as JAMA (The Journal of the American Medical Associa-
tion) and Lancet also include clinical trial reports for cancer
drugs and other drugs. Currently, we are obtaining the full-text
articles from these journals to extract broad types of drug–SE rela-
tionships from high-proﬁle clinical trial reports.6. Conclusions
In this study, we presented a system that combined both table
classiﬁcation and relationship extraction to extract anticancer
drug–SE pairs from tables imbedded in full-text oncological arti-
cles. We demonstrated that the statistical table classiﬁer was effec-
tive in classifying tables into SE-related and non-related categories
(precision: 0.711; recall: 0.941; F1: 0.810). The drug–SE pair
extraction from classiﬁed tables achieved a precision of 0.605, a
recall of 0.460, and an F1 of 0.520. We showed that cancer drug-
related toxicity knowledge contained in JCO tables was largely
complementary to that captured in FDA drug labeling. We showed
that side effects associated with cancer drugs positively correlated
with drug ‘on-target’ genes, drug metabolism genes, and disease
indications. Therefore, computational approaches to studying
these drug–SE pairs extracted from JCO tables, in combination with
pairs extracted from other data sources, can provide insight into
the molecular mechanisms underlying many observed side effectsin cancer patients and can also aid in the prediction of unknown
drug side effects and the repurposing of existing drugs for new dis-
ease indications.Funding
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